Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,467 shares of the biopharmaceutical company’s stock after buying an additional 883 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Gilead Sciences were worth $1,173,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $25,000. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $29,000. Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 241 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 216 shares during the period. Finally, Investment Research & Advisory Group Inc. boosted its holdings in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the topic of several research reports. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Morgan Stanley upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $111.38.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the transaction, the chief financial officer owned 165,110 shares in the company, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 0.6%

NASDAQ GILD opened at $111.06 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $66.34 and a 52 week high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a market cap of $138.15 billion, a P/E ratio of 23.38, a PEG ratio of 0.72 and a beta of 0.29. The company’s fifty day simple moving average is $107.26 and its 200-day simple moving average is $104.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the prior year, the company earned ($1.32) earnings per share. The firm’s revenue was down .3% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.